Medbase has been selected as an industrial partner in the Stroke Pharmaco-Omics Consortium (SPOCK), a major European research initiative exploring how pharmacogenomics can transform ischaemic stroke treatment and bring personalised medicine into everyday clinical practice.

1.4.2026

The SPOCK project is part of the EP PerMed / Horizon Europe programme and brings together leading European research organisations, healthcare providers, and technology partners. Together, the consortium develops and evaluates genotype-guided pharmacotherapy to improve outcomes for patients with ischaemic stroke and transient ischaemic attacks (TIA).

A major international clinical study in ischaemic stroke care

The project is coordinated by the University of Helsinki and led by Professor Mikko Niemi. Medbase contributes as an industrial partner, working in close collaboration with the consortium.

SPOCK is a large-scale international clinical study aiming to include approximately 2,250 patients across Finland, Sweden, Denmark and Spain. The study evaluates whether genotype-guided pharmacotherapy can reduce recurrent cardiovascular events while minimising adverse drug reactions in ischaemic stroke and TIA patients. Ultimately, the project aims to deliver safer, more effective, and truly personalised care for patients affected by ischaemic stroke across Europe.

By generating high-quality, prospective evidence from this large-scale study, SPOCK seeks to bridge knowledge gaps in pharmacogenetics and accelerate the adoption of genotype-guided therapy towards becoming a future standard in ischaemic stroke care.

Bringing pharmacogenomics into clinical practice

Medbase’s role in the project is to develop and deliver clinical decision support (CDS) that seamlessly integrates pharmacogenetic test results into patient care.

The solution delivers real-time, evidence-based and guideline-aligned recommendations – including optimal drug selection, dosing adjustments, and safer alternatives – directly to clinicians at the point of care.

In addition, the project evaluates how pharmacogenomic data can be standardised and integrated into clinical workflows and healthcare IT systems, supporting implementation across different healthcare environments.

Advancing personalised medicine in ischaemic stroke care by bringing pharmacogenomics into real-world clinical decision-making across Europe.

From research to real-world impact

While the clinical outcomes are central, SPOCK also focuses on how pharmacogenomics can be effectively implemented in everyday healthcare. The project addresses key challenges such as usability, interoperability, and scalability to support integration into routine clinical workflows.

– Participation in the SPOCK project strengthens Medbase’s position as a trusted research and development partner and highlights our role in bringing pharmacogenomics into real-world clinical decision-making – not just as content, but as actionable, integrated solutions, says Atte Auranen, CEO of Medbase.

– This project shows how clinical decision support can bridge research with patient care and brings us closer to making personalised medicine a standard in ischaemic stroke treatment.  

The project is expected to generate valuable insights into the effectiveness, implementation, and scalability of clinical decision support, contributing to improved quality, safety, and outcomes in healthcare across Europe.

More information about the project and Medbase’s role will be shared as the project progresses.